Pterygium Eye Diseases Pterygium
Conditions
Interventions
Participants will be randomized to one of the following groups:
Study group: Subconjunctival injection of Bevacizumab (2.5 mg/0.1 ml) followed by pterygium surgical excision with bare sclera techniqu
Sponsors
S. Luigi Gonzaga University Hospital
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1. Aged over 18 years 2. Pterygium in one/both eye(s) extending more than 1 mm across the limbus
Exclusion criteria
Exclusion criteria: 1. Pregnancy 2. Ocular surface disease or infection 3. Autoimmune disorders 4. Previous limbal or corneal surgery
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Recurrence of pterygium (defined by growth of fibrovascular tissue extending more than 1 mm across the limbus), assessed by ophthalmological examination during follow-up visits at 1 week, 1 month, 3 and 6 months after the second subconjunctival injection (for the study group) or after surgery (for the control group). | — |
Secondary
| Measure | Time frame |
|---|---|
| 1. Grading of pterygium vascularization (according to the scheme proposed by Tan et al., Arch Ophthalmol 1997), assessed by ophthalmological examination during follow-up visits at 1 day, 1 month, 3 and 6 months after the second subconjunctival injection (for the study group) or after surgery (for the control group) 2. Pterygium dimensions, assessed by comparison of ocular anterior segment photographs captured 1 week before treatment with pictures captured at 1 week, 1 month 3 and 6 months follow-up visits | — |
Countries
Italy
Outcome results
None listed